Ascenta Capital – Talk Bio

Actionable Insights Powered by AI

Ascenta Capital Closes $325 Million Inaugural Fund to Back Exceptional Development-Stage Biotechs

2 weeks ago talkbio0Tagged Ascenta Capital, biotechs, Clinical Trials, Early-stage, Evan Rachlin, Funds, Investments, multi-medicine platforms, portfolio companies, venture capital

Ascenta Capital; biotech investment; venture capital; $325M fund; clinical trials; multi-medicine platforms; Evan Rachlin; Lorence Kim; early-stage biotechs; portfolio companies

Cardurion Pharmaceuticals Raises $260M in Series B Funding to Challenge Statin-Dominated Cardiovascular Market

1 year ago talkbio0Tagged Administration occupational activities, Ascenta Capital, biotech, Blue color, Capital, Capital Management, Cardiovascular system, Cardurion, Farallon, fidelity, Genus: Digitalis, Granulovirus, Healthcare Opportunities, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Invus, Millennium, NEA, Research Company, Series B

Cardurion Pharmaceuticals, Series B Funding, Cardiovascular, Statins, Biotech, Bain Capital, Ascenta Capital, NEA, GV, Fidelity Management & Research Company, Millennium Management, Farallon Capital Management, Invus, Blue Owl Healthcare Opportunities, Delos Capital, Digitalis Ventures